Colton Brown

Colton Brown

Auto-generated profile, based on publicly available information

Colton Brown

Department of Pediatric General and Thoracic Surgery Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2026 in Seminars in Pediatric Surgery
Verified
Journal Article
Open access
CBColton G. Brown
Colton G. Brown
MRMarissa Ray
Marissa Ray
MCMarco Carpenter
Marco Carpenter
BFBraxton Forde
Braxton Forde
TSTarun Subramanian
Tarun Subramanian
LGLaura Galganski
Laura Galganski
Pivotal advancements in diagnostics have greatly improved early detection of disease in the fetus. Rapid diagnosis of prenatal disease, including many aneuploidies and single-gene disorders, is now possible. These capabilities present an opportunity for earlier interventions and involvement of multidisciplinary care for infants discovered to have genetic disorders. While advancements continue to be made surgically addressing anatomic pathologies, more recently, the scope of fetal medicine has expanded to include the treatment of genetic disease. This unique and growing group of conditions with potential prenatal therapeutic targets spans broadly to include inborn errors of metabolism, neurodegenerative disorders, hematologic conditions, and errors in hormone biosynthesis. Because many of these hereditary conditions begin exerting deleterious effects before birth, prenatal therapies are critical to minimize or potentially avoid postnatal consequences. Fetal treatments can leverage the benefits of early human development such as a selectively permissive blood-brain barrier and a naive immune system. These factors, along with a favorable vector-to-tissue mass ratio in the fetus, create ideal treatment conditions that are not present after birth. Together, improved prenatal diagnostics and safe minimally invasive approaches for the delivery of therapies in utero have opened a window to what was previously an inaccessible population: the fetal patient. This review summarizes current clinical strategies and emerging investigational approaches, including enzyme replacement, protein therapy, stem cell transplantation, and gene-targeted interventions.


4 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ADAaron M. Delman
Aaron M. Delman
ESEmily Schepers
Emily Schepers
SHStephen J Hartman
Stephen J Hartman
ZFZishaan Ahmed Farooqui
Zishaan Ahmed Farooqui
MRMarissa Ray
Marissa Ray
GTGregory M. Tiao
Gregory M. Tiao

16 October 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
MRMarissa Ray
Marissa Ray
RERory Edwards
Rory Edwards
CBColton Brown
Colton Brown
OHOlivia Hopper
Olivia Hopper
EREmily Rheaume
Emily Rheaume
MKMeera Kotagal
Meera Kotagal
Pediatric patients who experience firearm injury may be at risk for subsequent reinjury, yet the timing and predictors of recurrence remain poorly defined. Characterizing reinjury patterns at both individual and system levels is essential for informing targeted prevention strategies. We performed a retrospective review (2010-2024) of patients aged 0-18 years presenting with non-self-inflicted firearm injuries to two Level I pediatric and adult trauma centers. Cross-institutional database linkage was used to identify reinjury events. Cumulative incidence functions estimated reinjury risk over time, accounting for death as a competing risk. Univariate and multivariate Cox proportional hazards models evaluated independent predictors of reinjury. Among 834 patients (84.9% male, 79% Black; median age 17 years [IQR 15-18]), 67 died from their index injury and 75 sustained a subsequent firearm injury at a median of 22 months (IQR 12-61). No reinjury events occurred among children younger than 11 years. Cumulative reinjury incidence at one, three, and five years was 2.5% (1.4-3.6), 5.9% (4.2-7.5), and 7.8% (5.8-9.7), respectively. Assault-related index injury (aHR 2.18, 95% CI 1.10-4.35), lower injury severity (aHR 0.59, 95% CI 0.36-0.97), and treatment at an adult trauma center (aHR 3.43, 95% CI 1.46-8.06) were independently associated with increased reinjury risk. Firearm reinjury among pediatric patients is concentrated in adolescence and often occurs years after the initial event. Reinjured youth were more likely to have been assaulted, uninsured, and initially treated for relatively minor injuries-factors that may limit engagement with supportive services. These findings underscore the need for developmentally tailored violence-prevention and resource-linkage interventions initiated at the time of first injury.

29 October 2026 in Cancer Medicine
Verified
Journal Article
Open access
MRMarissa Ray
Marissa Ray
ASAlyssa Stetson
Alyssa Stetson
NNNicolas Noriega
Nicolas Noriega
SHStephen J Hartman
Stephen J Hartman
CBColton Brown
Colton Brown
Gregory M. TiaoGregory M. Tiao
Gregory M. Tiao
Relapse occurs in 10%–20% of children with hepatoblastoma and is associated with inferior outcomes, yet standardized management remains limited. Defining risk factors and relapse patterns, as well as the role of surgery, particularly transplantation, is critical to optimizing survival. A retrospective review was performed of patients aged 0–18 years diagnosed with hepatoblastoma from 2007 to 2024. Demographics, tumor characteristics, treatment course, relapse patterns, and outcomes were collected. Analyses included univariable and multivariable logistic regression, Kaplan–Meier survival estimation, and log‐rank testing. Among 135 patients, 98 (72.6%) achieved remission without relapse, 32 (23.7%) relapsed, and 5 (3.7%) experienced primary progression without remission. Older age, PRETEXT (pretreatment extent of disease) IV, metastatic disease at diagnosis, and macrovascular invasion were associated with relapse on univariable analysis, but only older age remained independently associated with relapse (adjusted odds ratio 1.27 per year, 95% confidence interval 1.05–1.53); PRETEXT IV and metastatic disease were not significantly associated with overall survival. Lung‐only relapse demonstrated favorable survival (100% alive), whereas combined liver and lung or extrahepatic relapse had poorer outcomes (40%–44% alive), although survival did not differ significantly across relapse sites ( p = 0.15). Of 54 liver transplant recipients, 44 underwent upfront transplantation, and 10 underwent salvage transplantation, with no significant difference in overall survival ( p = 0.90), although the salvage group was small. Relapse or progression after upfront transplantation occurred in 27% of recipients; lung‐only relapse again conferred favorable survival. Long‐term survival is achievable in relapsed hepatoblastoma, particularly for isolated pulmonary relapse. Older age, likely a surrogate for adverse tumor biology, was associated with relapse but did not preclude survival when aggressive multimodal therapy was used. Salvage transplantation achieved durable survival in selected patients and should be considered for unresectable intrahepatic relapse when extrahepatic disease is absent or controlled.